REDWOOD CITY, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (Nasdaq:SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the pricing of the underwritten public offering of 3,000,000 shares of its common stock at a public offering…Read More
Soleno Therapeutics Announces Pricing of Approximately 120 Million Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock andor PreFunded Warrants
